Kathmere Capital Management LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.6% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,830 shares of the biopharmaceutical company's stock after buying an additional 4,303 shares during the quarter. Kathmere Capital Management LLC's holdings in Gilead Sciences were worth $2,446,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Ballentine Partners LLC raised its stake in Gilead Sciences by 7.0% in the first quarter. Ballentine Partners LLC now owns 23,371 shares of the biopharmaceutical company's stock valued at $2,619,000 after purchasing an additional 1,535 shares in the last quarter. Omega Financial Group LLC acquired a new position in Gilead Sciences in the first quarter valued at about $206,000. Austin Wealth Management LLC acquired a new position in Gilead Sciences in the first quarter valued at about $212,000. Gateway Wealth Partners LLC raised its stake in Gilead Sciences by 7.4% in the first quarter. Gateway Wealth Partners LLC now owns 3,921 shares of the biopharmaceutical company's stock valued at $439,000 after purchasing an additional 271 shares in the last quarter. Finally, SteelPeak Wealth LLC raised its stake in Gilead Sciences by 142.5% in the first quarter. SteelPeak Wealth LLC now owns 129,186 shares of the biopharmaceutical company's stock valued at $14,475,000 after purchasing an additional 75,912 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer directly owned 620,268 shares of the company's stock, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is currently owned by company insiders.
Gilead Sciences Trading Down 4.3%
Shares of Gilead Sciences stock traded down $4.90 during midday trading on Friday, reaching $109.64. The company had a trading volume of 6,115,020 shares, compared to its average volume of 7,692,547. The stock has a fifty day moving average price of $107.74 and a 200 day moving average price of $104.61. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a market cap of $136.38 billion, a PE ratio of 23.08, a P/E/G ratio of 0.74 and a beta of 0.29. Gilead Sciences, Inc. has a fifty-two week low of $69.91 and a fifty-two week high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.32) earnings per share. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.
Analyst Ratings Changes
A number of research firms recently commented on GILD. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Oppenheimer decreased their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $111.38.
Check Out Our Latest Research Report on GILD
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
